272 related articles for article (PubMed ID: 26209901)
1. Novel Therapies for Eosinophilic Disorders.
Bochner BS
Immunol Allergy Clin North Am; 2015 Aug; 35(3):577-98. PubMed ID: 26209901
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
4. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Kuruvilla M
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
[No Abstract] [Full Text] [Related]
6. Eosinophilic disorders in children.
Wagelie-Steffen A; Aceves SS
Curr Allergy Asthma Rep; 2006 Nov; 6(6):475-82. PubMed ID: 17026874
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
8. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
9. Biological Modulators in Eosinophilic Diseases.
Sriaroon P; Ballow M
Clin Rev Allergy Immunol; 2016 Apr; 50(2):252-72. PubMed ID: 25129490
[TBL] [Abstract][Full Text] [Related]
10. Hypereosinophilic syndrome and mepolizumab.
Boucher RM; Gilbert-McClain L; Chowdhury B
N Engl J Med; 2008 Jun; 358(26):2838-9; author reply 2839-40. PubMed ID: 18579821
[No Abstract] [Full Text] [Related]
11. Hypereosinophilic syndrome and mepolizumab.
Verzegnassi F
N Engl J Med; 2008 Jun; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
[No Abstract] [Full Text] [Related]
12. Pharmacological regulation of human eosinophil apoptosis.
Kankaanranta H; Moilanen E; Zhang X
Curr Drug Targets Inflamm Allergy; 2005 Aug; 4(4):433-45. PubMed ID: 16101520
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
Iurlo A; Cattaneo D
Blood Rev; 2023 Mar; 58():101014. PubMed ID: 36153195
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report.
Pitini V; Teti D; Arrigo C; Righi M
Br J Haematol; 2004 Dec; 127(5):477. PubMed ID: 15566349
[No Abstract] [Full Text] [Related]
15. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Kay AB; Klion AD
Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
[TBL] [Abstract][Full Text] [Related]
16. Targeting eosinophils in asthma: current and future state of cytokine- and chemokine-directed monoclonal therapy.
Walsh GM
Expert Rev Clin Immunol; 2010 Sep; 6(5):701-4. PubMed ID: 20828276
[No Abstract] [Full Text] [Related]
17. Novel targeted therapies for eosinophilic disorders.
Wechsler ME; Fulkerson PC; Bochner BS; Gauvreau GM; Gleich GJ; Henkel T; Kolbeck R; Mathur SK; Ortega H; Patel J; Prussin C; Renzi P; Rothenberg ME; Roufosse F; Simon D; Simon HU; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2012 Sep; 130(3):563-71. PubMed ID: 22935585
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilic myocarditis in hypereosinophilic syndrome.
Roehrl MH; Alexander MP; Hammond SB; Ruzinova M; Wang JY; O'Hara CJ
Am J Hematol; 2011 Jul; 86(7):607-8. PubMed ID: 21681785
[No Abstract] [Full Text] [Related]
19. Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens.
Hayashi S; Isobe M; Okubo Y; Suzuki J; Yazaki Y; Sekiguchi M
Heart Vessels; 1999; 14(2):104-8. PubMed ID: 10651187
[TBL] [Abstract][Full Text] [Related]
20. Targeting eosinophils in allergy, inflammation and beyond.
Fulkerson PC; Rothenberg ME
Nat Rev Drug Discov; 2013 Feb; 12(2):117-29. PubMed ID: 23334207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
